Last reviewed · How we verify

BENZOYL PEROXIDE/ CLINDAMYCIN

Stiefel, a GSK Company · FDA-approved active Small molecule

Benzoyl peroxide kills acne-causing bacteria and reduces sebum production, while clindamycin is an antibiotic that inhibits bacterial protein synthesis.

Benzoyl peroxide kills acne-causing bacteria and reduces sebum production, while clindamycin is an antibiotic that inhibits bacterial protein synthesis. Used for Acne vulgaris.

At a glance

Generic nameBENZOYL PEROXIDE/ CLINDAMYCIN
SponsorStiefel, a GSK Company
Drug classTopical antibiotic combination
TargetBacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Benzoyl peroxide is a topical oxidizing agent that generates reactive oxygen species to kill Cutibacterium acnes (formerly Propionibacterium acnes) and has keratolytic properties. Clindamycin is a lincosamide antibiotic that binds to bacterial ribosomes and inhibits protein synthesis. Together, they provide synergistic antibacterial activity and reduce inflammation in acne lesions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: